HCV and HIV Coinfection
The Search for Host Genetic Fac ...
Though pursuit of host genetic factors that influence the pathogenesis of HIV began over two decades ago, progress has been slow. Initial genome-lev ...
Influenza and HIV: Lessons from ...
Influenza is a common respiratory disease in adults, including those infected with HIV. In the spring of 2009, a pandemic influenza A (H1N1) virus ( ...
Noninvasive Assessment of HIV-r ...
Highly active antiretroviral therapy has led to significant declines in infection-related mortality in HIVinfected patients. Cardiovascular disease ...
Adding Fuel to the Fire: Alcoho ...
Alcohol consumption adds fuel to the HIV epidemic in sub-Saharan Africa (SSA). SSA has the highest prevalence of HIV infection and heavy episodic dr ...
Topical Prophylaxis for HIV Pre ...
Strategies to protect against sexual transmission of HIV include the development of products formulated for topical application, which limit the tox ...
Preexposure Prophylaxis for HIV ...
Reducing the incidence of HIV remains one of our greatest public health challenges. However, there is growing optimism that preexposure prophylaxis ...
Renal Issues in HIV Infection
Kidney disease remains a prominent complication of HIV disease, despite beneficial effects of antiretroviral therapy on the natural history of HIV-a ...
Antiretroviral Therapy: A Key C ...
Transmission of HIV is critically dependent on the level of HIV viral load within blood and genital secretions. Antiretroviral therapy results in su ...
Improving the Diagnosis of Tube ...
The diagnosis of latent and active tuberculosis in the HIV-positive population is challenged by diminished sensitivity of conventional tests, atypic ...
HIV/HCV Co-infection: Pathogene ...
World-wide, hepatitis C virus (HCV) accounts for approximately 130 million chronic infections, with an overall 3% prevalence. Four to 5 million pers ...
Gene Therapy Strategies: Can We ...
Despite the tremendous advances in antiretroviral combination therapy over the last decade, eradication of HIV from the infected organism is still ...
Cancer Screening in Patients In ...
Non–AIDS-defining cancers are a rising health concern among HIV-infected patients. Cancer screening is now an important component of health maintena ...
Vitamin D in HIV-Infected Patie ...
Observational studies have noted very high rates of low 25(OH)D (vitamin D) levels in both the general and HIV-infected populations. In HIV-infected ...
Current Antiviral Therapy of Ch ...
The treatment of chronic hepatitis B is in constant evolution. Interferon, the first agent licensed for chronic hepatitis B treatment, has been supe ...
Hepatocellular Carcinoma Survei ...
Hepatocellular carcinoma (HCC) is a malignant tumor arising primarily in cirrhotic livers as a consequence of chronic hepatitis B or C virus infecti ...
Post-transplant Management of H ...
Prior to the availability of effective posttransplant immunoprophylaxis, outcomes following liver transplant for hepatitis B-related liver disease w ...
HCV and HIV Coinfection
Chronic hepatitis C (CHC) is estimated to affect about 20% of the 34 million individuals currently living with HIV worldwide, with greater rates (~ ...
Hepatitis C Viral Kinetics in t ...
In the last decade, hepatitis C virus (HCV) kinetics has become an important clinical tool for the optimization of therapy with pegylated-interferon ...
The Role of Hepatic Steatosis i ...
Chronic hepatitis B (CHB) infection is a global public health burden, and is associated with substantial morbidity and mortality. Although viral fac ...
Liver Transplantation for Hepat ...
Hepatitis C-positive liver transplantation (LT) patients present significant problems in post-transplant management. These patients are known to hav ...
Treatment of Chronic Hepatitis ...
The past standard-of-care (SOC) for treatment of the chronic hepatitis C virus (HCV) was the combination of peginterferon with ribavirin (P+R). Sus ...
Hepatitis B Vaccination: Curren ...
Hepatitis B virus (HBV) is the leading cause of chronic liver disease worldwide. Antiviral therapy for HBV is a safe and effective strategy for prev ...
Hepatitis C Virus and End Stage ...
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease in the world. It is particularly common in patients with end-stage ren ...
Current Management of HBV Antiv ...
Long-term administration of oral anti-hepatitis B virus (HBV) nucleoside or nucleotide analogues therapy (NUC) is the first-line treatment option fo ...
Hepatitis C Virus and Innate Im ...
The innate immune response represents the first line of defense against hepatitis C virus (HCV) infection. The response is an early, coordinated eff ...